anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Despite the potential negative impact of preoperative obesity on total hip arthroplasty (THA) outcomes, the association between preoperative and postoperative weight change and outcomes is much less understood. Therefore, this study aimed to determine the impact of preoperative and postoperative weight change and preoperative body mass index (BMI) on health care utilization, satisfaction, and achievement of minimal clinically important difference (MCID) for Hip Disability and Osteoarthritis Outcome Score Physical Function Short-Form (HOOS PS) and HOOS Pain.
METHODS: Patients who underwent primary elective unilateral THA between January 2016 and December 2019 were included (N = 2,868). Multivariable logistic regression assessed the association between BMI and preoperative and postoperative weight change on outcomes while controlling for demographic characteristics.
RESULTS: There was no association between preoperative weight change and prolonged length of stay (> 3 days), 90-day readmission, nonhome discharge, patient dissatisfaction at 1 year, or achievement of HOOS Pain or HOOS PS MCID. Postoperative weight loss was an independent risk factor for patient dissatisfaction at 1 year but was not associated with achievement of either HOOS Pain or HOOS PS MCID at 1-year postoperative. Preoperative obesity classes I to III were independent risk factors for nonhome discharge. Nevertheless, preoperative obesity class I and class II were associated with an increased probability of reaching HOOS Pain MCID. Preoperative BMI was not associated with an increased risk of patient dissatisfaction.
CONCLUSIONS: Preoperative weight change does not appear to influence health care utilization, satisfaction, or achievement of MCID in pain and function following THA. Postoperative weight loss may play a role as a risk factor for dissatisfaction following THA. Additionally, patients who had a higher baseline BMI may be more likely to see improvement in pain following THA. Therefore, when counseling obese patients for THA, surgeons must balance the risk of perioperative complications with the expectation of greater improvements in pain.
Participants in this intervention group will undergo a 10-week melatonin supplement intervention period, where melatonin supplement (Natrol®, Chatsworth CA) will be provided 30 minutes before bedtime. The prescription time (i.e. 30 minutes before bedtime) and the dosage of 3mg will be used because these are optimal for most of the participants as suggested by Malow and colleagues. 1 mg and 9 mg are not suggested to ensure the effectiveness of the intervention while preventing the potential daytime sleepiness. Similar to the aforementioned intervention, adherence of the intervention will be assessed at T2.
PURPOSE: A composition containing Castaneae crenata shell extract for preventing and treating a fatty liver is provided to suppress the activation of fatty liver biosynthetase and carnitine palmitoyl transferase. CONSTITUTION: A pharmaceutical composition for preventing and treating a fatty liver contains Castaneae crenata shell extract as an active ingredient. The fatty liver is an alcoholic fatty liver. The pharmaceutical composition additionally contains a pharmaceutically acceptable carrier. A composition for suppressing fatty acid synthetase(FAS) activation contains Castaneae crenata shell extract as an active ingredient. A composition for enhancing carnitine palmitoyltransferase-1(CPT) activation contains Castaneae crenata shell extract as an active ingredient.
PURPOSE: An antibacterial agent composition containing urea, thiourea and sulfamide derivatives as an effective ingredient is provided. Therefore, it shows antimicrobial activity and an antibacterial spectrum against wide pathogens containing various Gram positive bacteria and thus is expected to be useful in the prevention and treatment of animal disease caused by bacterial infection. CONSTITUTION: The antibacterial agent composition contains urea, thiourea, sulfamide derivatives and a pharmaceutically acceptable salt, hydrate and solvate thereof represented by the formula I. In formula, each of X and Y is hydrogen, chlorine or trifluoromethyl, Z is -CO-, -CS- or -SO2-. Therefore, it exhibits excellent antibacterial activity against methicillin-resistant Staphylococcus aureus. It can be administered in the form of injectable formulations or oral formulations.
The invention discloses a nutmeg flavor grape fruit wine and a brewing method thereof. The brewing raw material comprises grape, nutmeg, traditional Chinese medicine compound and water. The raw grape wine and the raw nutmeg wine are mixed into the nutmeg flavor grape fruit wine. The fruit wine preparation technology is simple, is easily realized, has obvious economic value and is suitable for large-scale production. The alcohol concentration of the wine is low. The nutmeg flavor grape fruit wine can meet the public requirements, and especially, is suitable for people suffering from spleen and stomach discomfort.
FIELD: medicine, genetic therapy. SUBSTANCE: invention relates to method for preparing genetically modified cells. Method involves isolation of cells from blood or body liquids, culturing prepared cells in medium for cells culturing containing gangliosides, phospholipids, glycolipids and/or endothelial cells growth factors, by optional, immortalization of prepared cells by their transformation with oncogene taken among group consisting of mutated genes cdk-4, cdk-6 and cdk-2, activation of protooncogene or inactivation of suppressor gene, transfection of prepared cells using construction of nucleic acid for genetic therapy comprising gene-effector that can be activated with using useful promoter systems specifically to cell, specifically to mitosis, specifically to virus and/or by hypoxia. The advantage of method is the development of endothelial cells as cellular carriers of transgenes in genetic therapy. EFFECT: valuable medicinal properties of cells. 18 cl, 1 dwg, 2 tbl
<P>PROBLEM TO BE SOLVED: To provide a novel crosslinked DNA insoluble in water and a method of using the same as a material for environmental cleanup.  <P>SOLUTION: When an aqueous solution of a water-soluble DNA (for example, DNA derived from the spermary of a salmon) or its aqueous film on a support or a thin aqueous film liquid of a water-soluble DNA on a support is irradiated with an ultraviolet ray having a wavelength in the range of 250-270 nm, the DNA on the support is changed into an immobilized, water-insoluble, and crosslinked product. In the same manner, for example, by irradiating an aqueous solution of a water-soluble DNA, in which a cellulose fiber nonwoven fabric is immersed, with ultraviolet rays having a wavelength in the range of 250-270 nm, a cellulose fiber nonwoven fabric coated with a water insoluble crosslinked polymer of the DNA is formed. This crosslinked product adsorbs an intercalating agent into DNA or an endocrine-disrupting chemical in water even at a very low concentration in an extremely high yield. The crosslinked product similarly adsorbs a toxic metal such as an Hg ion relative to water in an immobilizing manner. Accordingly, this crosslinked product is useful as an environmentally purifying material.  <P>COPYRIGHT: (C)2008,JPO&INPIT
For each transfused patient (index patient), one matched non-transfused control will be identified and included in the control group. The matching will be conducted using four criteria in hierarchical order: gender; age ± 10%; baseline Hemoglobin level (± 15 g/L); and Pediatric Risk of Mortality III score (PRISM III score ± 10%).
Tepotinib is approved for the treatment of patients with non-small-cell lung cancer harboring MET exon 14 skipping alterations. While edema is the most prevalent adverse event (AE) and a known class effect of MET inhibitors including tepotinib, there is still limited understanding about the factors contributing to its occurrence. Herein, we apply machine learning (ML)-based approaches to predict the likelihood of occurrence of edema in patients undergoing tepotinib treatment, and to identify factors influencing its development over time. Data from 612 patients receiving tepotinib in five Phase I/II studies were modeled with two ML algorithms, Random Forest, and Gradient Boosting Trees, to predict edema AE incidence and severity. Probability calibration was applied to give a realistic estimation of the likelihood of edema AE. Best model was tested on follow-up data and on data from clinical studies unused while training. Results showed high performances across all the tested settings, with F1 scores up to 0.961 when retraining the model with the most relevant covariates. The use of ML explainability methods identified serum albumin as the most informative longitudinal covariate, and higher age as associated with higher probabilities of more severe edema. The developed methodological framework enables the use of ML algorithms for analyzing clinical safety data and exploiting longitudinal information through various covariate engineering approaches. Probability calibration ensures the accurate estimation of the likelihood of the AE occurrence, while explainability tools can identify factors contributing to model predictions, hence supporting population and individual patient-level interpretation.
FIELD: biochemistry.SUBSTANCE: group of inventions relates to an improved method for biochemical extraction of an IL-15/IL-15Rα-based conjugate in monomer form and a pharmaceutical composition comprising an effective amount of a composition comprising monomeric conjugates of IL-15/IL-15Rα. Method involves purification of a clarified supernatant from a culture medium of a transformed host cell expressing a conjugate having the amino acid sequence SEQ ID NO: 16 or SEQ ID NO: 17. Purification is carried out by means of anion-exchange chromatography (AEX) at pH equal to or higher than 7.0, preferably equal to or higher than 7.5. Further, obtained eluate is purified by chromatography of hydrophobic interaction (HIC) carried out in buffer solution containing 0.75 M - 2.5 M of ammonium sulphate, preferably 1 M - 2 M of ammonium sulphate. Conjugates are eluted in gradient from 2 M to 0 M, preferably from 1.5 to 0 M of ammonium sulphate. Obtained composition contains at least 80 % conjugates in a monomer form, which satisfies their use in a pharmaceutical composition for treating cancer in a subject.EFFECT: invention enables to obtain a conjugate with high output and reproducibility, with purity of more than 98 %, without detectable level of endotoxin, heat shock proteins or residual DNA.8 cl, 7 dwg, 3 tbl
The present invention discloses a smart wearable device comprising a connecting unit, a first sensory module, a second sensory module and an extending unit, and the smart wearable device is maintained on a wearer via a plurality of contact cushion. The connecting unit comprises a connecting belt, a first positioning groove, a first positioning unit, a second positioning groove and a second positioning unit. The connecting belt has a first end and a second end, and the first end forms a paralleled line or a perpendicular line with the second end. The first sensory module comprises a first sensory unit, and the second sensory module comprises a second sensory unit. The extending unit comprises an extending belt, a first extending zone, a second extending zone, a first fastening unit and a second fastening unit. When the connecting belt connects to the extending belt, the extending belt lies upon the perpendicular line, and the first fastening unit connects to the first contact cushion so that the first extending zone is kept on the upper limb of the wearer, and the second fastening unit connects the first sensory unit.
Flumazenil is well tolerated at the recommended doses in individuals who have no tolerance to (or dependence on) benzodiazepines. The recommended doses and titration rates in anesthesia and conscious sedation (0.2 mg to 1 mg given at 0.2 mg/min) are well tolerated in patients receiving the drug for reversal of a single benzodiazepine exposure in most clinical settings. (See ADVERSE REACTIONS.) The major risk will be resedation because the duration of effect of a long-acting (or large dose of a short-acting) benzodiazepine may exceed that of flumazenil. Resedation may be treated by giving a repeat dose at no less than 20-minute intervals. For repeat treatment, no more than 1 mg (at 0.2 mg/min doses) should be given at any one time and no more than 3 mg should be given in any one hour.
This is a prospective, randomized, double blinded stroke intervention study. Patients presenting with hyperglycemia (blood glucose level = or \> than 150mg/dl) and acute stroke symptoms within 12h of onset will be randomized to either treatment with PGZ or placebo. Patients will receive oral drug vs placebo once daily for three consecutive days. Blood samples will be obtained at baseline and during the subsequent three days to collect various biomarkers of the stress-immune response following ischemic stroke. Clinical outcomes (NIH-SS and mRS) will be determined at 3 months. Secondary outcome measures are changes in the various blood biomarkers comparing both study groups.
Patients receive cabozantinib S-malate PO QD on days 1-21. Cycles repeat every 21 days until the completion of radiation therapy in the absence of disease progression or unacceptable toxicity. Beginning cycle 1 day 8, patients also undergo standard of care radiation therapy for 5-6 weeks.
1333996 Anti-tumour agent from streptococci CHUGAI SEIYAKU KK 28 Sept 1971 [30 Sept 1970] 45239/71 Heading A5B An anti-tumour agent is obtained by subjecting haemolytic streptococci cells to enzymatic bacteriolysis and collecting the waterinsoluble material of the lysate. The product can be mixed with a stabilizer, e.g. an amino acid or a sugar, and dried, e.g. by freezedrying, or used as a suspension in a physiologically acceptable medium, e.g. saline. The enzyme may be one prepared from a lysate of Bacteriosphage ATCC No. 21597-b-infected Group C Streptococcus sp or one produced by specified strains of Flavobacterium, Streptomyces albus, Streptomyces rutgersensis or Streptomyces griseus.
OBJECTIVES: Whether COVID-19 leads to long-term pulmonary sequelae or not remains unknown. The aim of this study was to assess the prevalence of persisting radiological pulmonary fibrotic lesions in patients hospitalized for COVID-19.
MATERIALS AND METHODS: We conducted a prospective single-center study among patients hospitalized for COVID-19 between March and May 2020. Patients with residual symptoms or admitted into intensive care units were investigated 4 months after discharge by a chest CT (CCT) and pulmonary function tests (PFTs). The primary endpoint was the rate of persistent radiological fibrotic lesions after 4 months. Secondary endpoints included further CCT evaluation at 9 and 16 months, correlation of fibrotic lesions with clinical and PFT evaluation, and assessment of predictive factors.
RESULTS: Among the 1151 patients hospitalized for COVID-19, 169 patients performed a CCT at 4 months. CCTs showed pulmonary fibrotic lesions in 19% of the patients (32/169). These lesions were persistent at 9 months and 16 months in 97% (29/30) and 95% of patients (18/19) respectively. There was no significant clinical difference based on dyspnea scale in patients with pulmonary fibrosis. However, PFT evaluation showed significantly decreased diffusing lung capacity for carbon monoxide (p < 0.001) and total lung capacity (p < 0.001) in patients with radiological lesions. In multivariate analysis, the predictive factors of radiological pulmonary fibrotic lesions were pulmonary embolism (OR = 9.0), high-flow oxygen (OR = 6.37), and mechanical ventilation (OR = 3.49).
CONCLUSION: At 4 months, 19% of patients investigated after hospitalization for COVID-19 had radiological pulmonary fibrotic lesions; they persisted up to 16 months.
CLINICAL RELEVANCE STATEMENT: Whether COVID-19 leads to long-term pulmonary sequelae or not remains unknown. The aim of this study was to assess the prevalence of persisting radiological pulmonary fibrotic lesions in patients hospitalized for COVID-19. The prevalence of persisting lesions after COVID-19 remains unclear. We assessed this prevalence and predictive factors leading to fibrotic lesions in a large cohort. The respiratory clinical impact of these lesions was also assessed.
KEY POINTS: • Nineteen percent of patients hospitalized for COVID-19 had radiological fibrotic lesions at 4 months, remaining stable at 16 months. • COVID-19 fibrotic lesions did not match any infiltrative lung disease pattern. • COVID-19 fibrotic lesions were associated with pulmonary function test abnormalities but did not lead to clinical respiratory manifestation.
The present invention relates to novel kidney related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "kikdney antigens", and the use of such kidney antigens for detecting disorders of the kidney, particularly the presence of kidney cancer and kidney cancer metastases. More specifically, isolated kidney associated nucleic acid molecules are provided encoding novel kidney associated polypeptides. Novel kidney polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human kidney associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the kidney, including kidney cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.
PROBLEM TO BE SOLVED: To provide a method for deactivating the postcuring occurring in thickening of a silicone fluid and an org. solvent in a silicone elastomer. SOLUTION: This method for thickening a silicone fluid and an org. solvent in a silcone elastomer comprises the step of reacting (A) a polysiloxane having ≡Si-H groups with (B) an alkane such as an α,ω-diene in the presence of (C) a catalyst and (D) a solvent; the step of continuing the mixing and reaction until an elastomer is formed by the crosslinking and addition of ≡Si-H groups extending over double bonds of the alkane; the step of adding an additional solvent and (E) a postcuring the elastomer; and applying shearing force to the solvent, the postcuring deactivator, and the elastomer until a paste is formed. The postcuring deactivator used is selected from among (i) a strong platinum complex-forming agent, (ii) an ≡SiH deactivator such as vinylsiloxane, and (iii) an unsatd. org. compd.
This cross-sectional study sought to assess the prevalence of atrial fibrillation (AF) diagnosis in Greenland among various age groups and examine the corresponding quality of care. We collected data from Greenland's electronic medical records and evaluated the quality of care using six internationally recommended indicators, which are: percentage of AF patients with an assessment of smoking status within the previous year, an assessment of body mass index within the previous year, assessment of blood pressure within the previous year, measurement of thyroid stimulating hormone (TSH), treatment with an anticoagulant and percentage of patients with a measurement of serum-creatinine. We found the prevalence of AF among patients aged 20 years or older in Greenland to be 1.75% (95% CI 1.62-1.88). We found an increasing prevalence of AF with age and a greater proportion of men than women until the age of 74 years. Our study suggests that the associated quality of care could be higher as the requirement of only one of the six quality indicators was met. A lack of registration may partly explain this, and initiatives to improve the quality of care are recommended.
<P>PROBLEM TO BE SOLVED: To provide a method and a medicine for increasing neural stem cell numbers.  <P>SOLUTION: The method and the medicine are provided for increasing the neural stem cell numbers or neural neogenesis by using prolactin which is a polypeptide hormone. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, administration of a medicine containing prolactin can increase the number of neural stem cells. The neurodegenerative diseases especially include Alzheimer disease, disseminated sclerosis, Huntington disease, amyotrophic lateral sclerosis, and Parkinson disease.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Intervention: Increasing awareness to cardiac rehabilitation programs: Patients received a written and oral short explanation on the importance and benefits of cardiac rehabilitation (CR) participation, and information on available programs. They were telephoned 2 weeks after hospital discharge to encourage them to enroll at a cardiac rehabilitation program (CRP). In addition, physicians and nurses at the cardiothoracic units participated in a 1-hour seminar on CR. A recommendation to the general physician to refer the patient to CRP was added to the letter of discharge from hospital.
This group will receive 8 weeks of upper and lower body plyometric exercises protocol. The session will last for 60 minutes and 3 time per week. 1-minute rest period is there between each exercise and each repetition and 3-5 minute for each set.
BACKGROUND: Our goal was to identify what impact chronic kidney disease (CKD) and its associated risk factors, such as body mass index (BMI), diabetes and hypertension, have on preeclampsia and other adverse pregnancy outcomes in the CKD population.
METHODS: This was a population-based cohort study of women with CKD who had a pregnancy from 2010 to 2022 (n = 95). At the time of the woman's pregnancy, data was collected on demographics, clinical measures, BMI, CKD etiology and other renal parameters. Outcomes included preeclampsia, pre-term delivery, and low birth weight.
RESULTS: Pre-pregnancy BMI increased over time in patients with CKD, with a median (interquartile range) BMI of 25 (22-29) prior to 2016 and 29 (25-34) after 2016 (p = 0.01). There were significant trends of increasing age at delivery and decreasing pre-pregnancy estimated glomerular filtration rate (eGFR) by delivery year. Preeclampsia affected nearly half of pregnancies in this cohort. In multivariate analyses, BMI and chronic hypertension did not impact the odds of preeclampsia, preterm delivery or low birth weight, though a CKD etiology of diabetes (19/20 with type I diabetes), was associated with a significant increase in preeclampsia risk (odds ratio (OR) 7.41 (95 % CI 2.1-26.1)). Higher pre-pregnancy eGFR was associated with a lower odds of preterm delivery (OR 0.81 (95 % CI 0.67-0.98)) per 10 ml/min/1.73 m2).
CONCLUSION: Pre-pregnancy BMI significantly increased over time, similar to the general population. While preeclampsia was common in CKD patients, outcomes were associated with eGFR and CKD etiology as opposed to BMI and chronic hypertension.